GW Pharmaceuticals company

GW Pharmaceuticals was founded in 1998 and is listed on both the NASDAQ Global Market (GWPH) and AIM, a market of the London Stock Exchange,. GW is licensed by the UK Home Office to work with a range of controlled drugs for medical research purposes. The Group's lead programme is the development of a product portfolio of cannabinoid prescription medicines to meet patient needs in a wide range of therapeutic indications, including Sativex® Oromucosal Spray and Epidiolex® for childhood epilepsy.
Technology: P4 Medicine
Industry: Regenerative Medicine
Headquarters: Histon, Cambridgeshire, United Kingdom
Founded Date: 6-20
Employees Number: 251-500
Funding Status: IPO
Investors Number: 1
Total Funding: $568.1M
Estimated Revenue: $50M to $100M
Last Funding Type: Post-IPO Equity

Visit Website
info@gwpharm.com
Register and Claim Ownership